Farokhzad pointed to several large-scale deployments as evidence of platform adoption, including a 20,000-sample population study with Korea University and a 10,000-sample project in collaboration with Discovery Life Sciences. He said studies of that magnitude were not previously feasible with traditional mass spectrometry proteomics approaches, which he characterized as lacking the depth and scalability needed for standardized processing of tens of thousands of samples.Chief Executive Officer Omid Farokhza ...

Q4 & FY 2025 Earnings Call February 26, 2026 Safe harbor disclosures Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact could be deemed forward-looking. These forward- looking statements relate to future events or results of Seer, Inc. (the "Company") and involve known and unknown risks, uncertainties and other factors that may cause the actual r ...

REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a tax benefit preservation plan (“NOL Plan”) designed to help preserve and protect Seer’s valuable income tax net operating loss carryforwards and other tax assets (“NOLs”). As of December 31, 2025, Seer had approximately $262 million of NOLs. These NOLs, most of which are not currently subjec ...

REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Generated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during the full year ...

Core Insights - Seer, Inc. is participating in the 2026 U.S. Human Proteome Organization Annual Conference, showcasing its Proteograph Product Suite which addresses complex questions in major disease areas and supports clinical and population health applications [1][2] Company Participation and Presentations - Seer will be featured in over a dozen scientific presentations at the conference, highlighting the adoption of nanoparticle-enabled proteomics in translational and population-scale research [2][7] - The company will host a breakfast symposium on February 24, where Dr. Sasha A. Singh will present findings on using the Proteograph Product Suite to profile plasma in a mouse model of atherosclerosis, achieving a tenfold increase in proteome depth compared to conventional methods [5] Technological Advancements - The Proteograph Product Suite is enabling deeper, scalable, and reproducible mass spectrometry measurements of the human proteome, which is crucial for advancing translational research [4][10] - The technology allows for the quantification of over 5,000 proteins from just 75 µL of plasma, addressing challenges in detecting low-abundance proteins [5] Research Focus Areas - Presentations at the conference will cover various disease areas including cardiovascular disease, neurodegeneration, aging biology, and oncology, demonstrating the broad application of deep, scalable proteomics [2][7] - Nathan Basisty will discuss the translation of aging biology into biomarkers and therapeutic strategies during a plenary session, emphasizing the role of proteomic technologies [6] Industry Impact - The conference reflects a broader shift in proteomics towards high-throughput workflows that enhance biological insights across multiple disease areas [10] - Seer's technology is positioned as a key player in advancing the field of proteomics, supporting reproducible research at scale [4][11]

Company Participation - Seer, Inc. will participate in the TD Cowen 46 Annual Health Care Conference in Boston, MA [1] - Management is scheduled for a fireside chat on March 4 at 11:10 a.m. Eastern Time [2] Company Overview - Seer, Inc. is a pioneer in deep, unbiased proteomics, providing insights with unprecedented scale, speed, precision, and reproducibility [3] - The Proteograph Product Suite integrates proprietary engineered nanoparticles, streamlined automation, optimized consumables, and advanced analytical software [3] - Seer's technology addresses challenges faced by traditional proteomic methods, which often struggle with inconsistent data and limited throughput [3] - The products are intended for research use only and are not designed for diagnostic procedures [3]

Core Insights - Seer, Inc. announced a significant genome-wide association study (GWAS) published in Nature Genetics, demonstrating the importance of mass spectrometry in validating protein changes and establishing reliable drug targets and clinical biomarkers [1][10] Group 1: Study Overview - The GWAS involved approximately 1,600 blood samples from diverse ethnic backgrounds, with a discovery cohort of 1,260 and a replication cohort of 325, leading to the detection of 5,753 proteins and quantification of 1,980 proteins in at least 80% of participants [2] - Researchers identified 364 protein quantitative trait loci (pQTLs) associated with protein abundance, with 102 of these replicated in the independent cohort, including 35 previously unreported signals [3] Group 2: Methodology and Findings - Traditional affinity-based proteomics can produce erroneous signals due to epitope effects, where genetic variants alter binding sites, leading to false associations between protein expression and genetic variants [4] - The Proteograph's mass spectrometry approach allows for direct measurement of proteins at the peptide level, effectively mitigating confounding effects and confirming true biological changes [5][6] Group 3: Implications for Research and Development - The study emphasizes that mass spectrometry validation is crucial for ensuring the reliability of protein measurements, which can enhance drug discovery and biomarker development by reducing technical noise and increasing the likelihood of clinical success [9][10] - The findings suggest that datasets relying solely on affinity reagents may contain a significant number of false associations, underscoring the need for mass spectrometry validation in genetic association studies [6][7] Group 4: Future Directions - As proteomics integrates with genomics and clinical data, the accuracy of these datasets will be vital for supporting drug targets and translational medicine, positioning Seer to lead in population-scale proteomics [11]

Core Insights - Seer, Inc. announced a significant genome-wide association study (GWAS) published in Nature Genetics, demonstrating the importance of mass spectrometry validation in establishing reliable drug targets and clinical biomarkers [1][10] Group 1: Study Overview - The study involved approximately 1,600 blood samples from diverse ethnic backgrounds, with a discovery cohort of 1,260 and a replication cohort of 325, utilizing Seer's Proteograph workflow [2] - A total of 5,753 proteins were detected, with 1,980 quantified in at least 80% of participants [2] Group 2: Findings and Implications - Researchers identified 364 protein quantitative trait loci (pQTLs) associated with protein abundance, with 102 replicating in the independent cohort, including 35 previously unreported signals [3] - The study highlighted that up to one-third of protein-gene associations reported by affinity-based assays do not replicate, underscoring the necessity for accuracy in proteogenomics [4][7] Group 3: Methodology and Technology - Seer's Proteograph platform employs mass spectrometry to measure proteins directly at the peptide level, mitigating confounding effects from affinity reagents [5][6] - The study compared mass spectrometry results with two major affinity-based proteomics resources, confirming that mass spectrometry is crucial for reliable proteomic analysis [6] Group 4: Future Directions - The findings strengthen confidence in drug discovery and biomarker development by ensuring that selected targets reflect genuine biological signals rather than technical noise [9] - The study positions proteomics as a population-ready science, essential for supporting drug targets and biomarkers with the rigor needed for clinical impact [11]

Summary of Seer Conference Call (November 20, 2025) Company Overview - **Company**: Seer (NasdaqGS:SEER) - **Industry**: MedTech Diagnostics and Proteomics - **Product**: Proteograph Product Suite, including Proteograph One and SP200 Key Points and Arguments Product Development and Performance - Seer launched the Proteograph Product Suite to enable deep, unbiased proteomic analysis at scale, significantly improving throughput and reducing costs compared to earlier iterations [3][4] - The latest product, Proteograph One, was launched in June 2025, allowing customers to conduct larger studies with reduced assay time and increased sample throughput [4][5] - Notable studies include a 20,000-sample study by Korea University and a $50 million NIH-funded multi-center grant for a 50,000-sample study, where Seer was selected as the sole proteomic platform [5][6][7] Customer Validation and Publication Velocity - Since the launch of the first product in 2021, 66 customer papers have been published, with 13 published in Q3 2023 alone, indicating increasing customer validation and biological insights [7][8] - The establishment of Prognomic, a spin-out focused on liquid biopsy, has led to the development of a best-in-class lung cancer test, showcasing the effectiveness of Seer's platform [8][9] Market Adoption and Customer Feedback - Customer feedback on the Proteograph One has been positive, with a significant increase in instrument placements from 11 in the previous year to nearly 30 in the first nine months of 2025 [10][11] - The platform is being adopted for various applications, including neurodegenerative diseases and biomanufacturing, demonstrating its versatility [11][12] Strategic Partnerships - Seer has formed a partnership with Thermo, enhancing their market presence through co-sales, which allows Thermo sales representatives to offer Seer's Proteograph alongside their mass spectrometry instruments [25][26] - The combination of Seer's technology with Thermo's instruments provides a significant increase in the depth of proteomic analysis, achieving 8-10 times more protein identification compared to Thermo's instruments alone [26][27] Commercial Strategy and Customer Engagement - Seer's stack and Strategic Instrument Placement (SIP) programs have been effective in driving platform adoption, with a significant portion of instrument placements coming from former stack customers [30][33] - The SIP program allows customers to borrow instruments, facilitating adoption in budget-constrained academic and government settings [32][33] Financial Outlook and Capital Allocation - Seer ended Q3 2025 with approximately $251 million in cash and reaffirmed a break-even runway, focusing on diligent capital management while investing in innovation [35][37] - The company aims to reach a revenue scale of around $100 million, leveraging its strong balance sheet to potentially acquire less capital-intensive technologies [39][40] Future Developments - Seer anticipates an increase in population-scale studies, predicting that 2026 will see the first 100,000-sample study conducted using mass spectrometry [41][42] - The company is focused on generating biological insights from these studies to drive revenue growth [42] Additional Important Insights - The scientific community's skepticism towards new platforms is acknowledged, emphasizing the importance of evidence and robust performance in gaining institutional confidence [13][14] - The complexity of proteomics is highlighted, with a call for deeper analysis at the peptide level to uncover significant biological variations that could inform health and disease understanding [19][20][24]

Core Insights - Seer, Inc. is showcasing new data at the HUPO World Congress 2025, highlighting the transformative impact of deep, scalable proteomics on human disease research [1][2] - The company's Proteograph Product Suite is facilitating research in cardiovascular, oncology, and aging biology, enabling scientists to translate complex biological signatures into actionable insights [1][3] Company Highlights - Seer's participation at HUPO 2025 includes over a dozen scientific presentations, with significant contributions such as two invited talks and sixteen posters, demonstrating the growing adoption of the Proteograph platform [2] - The CEO of Seer emphasized that proteomics has evolved to a new level of scalability and relevance, bridging molecular insights to clinical applications [3] Research Focus - The Seer Breakfast Symposium will feature discussions on cardiac dysfunction and aging-related decline, showcasing the use of deep proteomics to identify clinically relevant biomarkers [4] - Presentations will cover various studies, including deep plasma proteomics revealing disease mechanisms and biomarkers for cardiovascular failure and aging [4][5] Scientific Contributions - Multiple scientific presentations will highlight the capabilities of Seer's technology, including high-throughput plasma proteome profiling and insights into biomarkers predictive of readmission risk in heart failure [5][6][7] - The studies presented will also explore glycoproteomics, cancer cohort biomarker discovery, and extracellular vesicle biology, showcasing the breadth of Seer's impact across different research areas [6][8][9] Technological Advancements - Seer's Proteograph platform integrates engineered nanoparticles, automation, and advanced analytical software, addressing challenges faced by traditional proteomic methods [13] - The platform is noted for its ability to deliver insights with unprecedented scale, speed, precision, and reproducibility, setting a new standard in the field of proteomics [13]